CASC
VRCA icon

Coppell Advisory Solutions Corp’s Verrica Pharmaceuticals VRCA Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20
Closed -$550 – 1066
2022
Q4 		$550 Buy
+20
New +$534 ﹤0.01% 1008

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Coppell Advisory Solutions Corp's VRCA Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Verrica Pharmaceuticals (VRCA) in Q1 2023, closing a stake of 20 shares — an estimated $550 sold.

Coppell Advisory Solutions Corp first reported a position in VRCA in Q4 2022 and held it in 1 quarter. The position peaked at $550 in Q4 2022. 59 funds tracked by Wall St. Rank hold VRCA as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Verrica Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 20 Verrica Pharmaceuticals shares in Q1 2023, an estimated $550.
  • Coppell Advisory Solutions Corp first reported a position in Verrica Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Verrica Pharmaceuticals position peaked at $550 in Q4 2022.
  • 59 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.